We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Wize Pharma

News List

Wize Pharma Announces Positive Results for Dry Eye Syndrome in Sjögren's Syndrome americanpharmaceuticalreview
November 25, 2020
Wize Pharma reported topline results from its Phase IV clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome.
Wize Pharma Completes Phase IV Study of LO2A for Dry Eye Syndrome with Sjögren's Syndrome americanpharmaceuticalreview
May 12, 2020
Wize Pharma has completed treating patients in its Phase IV clinical trial of its prescription eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome.
Wize Pharma raises $1.14 Million biospectrumasia
March 05, 2018
A portion of the proceeds will be used for clinical studies that are evaluating the efficacy of LO2A in the treatment of dry eye syndrome